NCT07455721: ADENOCS

Central Sensitization in Women With Adenomyosis: Prevalence, Risk Factors, and Therapeutic Failure

Active, enrolled Last updated 6 March 2026

What this trial tests

trial in Adenomyosis in 1,200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 December 2025

Primary endpoint
9 December 2027

30 June 2028

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	1,200
Start date	9 December 2025
Primary completion	9 December 2027
Estimated completion	30 June 2028
Sites	14 locations across Italy

Conditions studied

• Adenomyosis — all drugs for Adenomyosis →

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

Adults 18 to 50, female only, with Adenomyosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, prospective, multicenter, non-profit study. The study aims to investigate the association between the Central Sensitization Inventory (CSI) score and the presence of Central Sensitization Syndrome (CSS) in women with adenomyosis, identifying a potential predictive threshold value. Additionally, the study aims to:

Estimate the prevalence of Central Sensitization (CS) in women with adenomyosis using the previously defined cut-off value;

Identify risk factors for CS in the study population;

Examine the relationship between CSI scores and concomitant pain symptoms/pain-related conditions;

Investigate the association of CSI scores and the identified cut-off with pain persistence at 6 months in relation to the pharmacological or surgical treatment performed;

Assess changes in CSI scores at 12 months from the initiation of pharmacological therapy or surgical intervention, both in women with improvement of pain symptoms and in those with persistent pain;

Develop a short Italian version of the CSI to be used in women with adenomyosis.

Participants aged 18-50 years attending the outpatient clinics of the participating centers with an ultrasound diagnosis of adenomyosis (defined as at least two features according to MUSA criteria, including one direct feature) will be enrolled. Patients will be treated according to standard clinical practice, ensuring the highest quality of care, and will not undergo additional visits beyond routine care.

At baseline (T0), relevant demographic and medical history data will be collected. Pain scores will be assessed using the Numerical Rating Scale (NRS), pelvic floor hypertonia will be evaluated via bimanual gynecological examination, and a transvaginal ultrasound will be performed. The indication for pharmacological therapy or surgical intervention will be recorded, and the CSI questionnaire will be administered.

At the 6- and 12-month follow-ups (T1 and T2, respectively), the gynecologist will update medical history, evaluate pain scores (NRS), assess adherence to pharmacological therapy (if prescribed at T0), and record postoperative course and complications (if the patient underwent surgery). The bimanual gynecological examination and transvaginal ultrasound will be repeated. At the 12-month visit, the gynecologist will repeat the T1 assessments and re-administer the CSI questionnaire.

A total of 1,200 patients will participate in this study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.